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Abstract
Background: Burkholderia contaminans is one of the 20 closely related bacterial of the Burkholderia cepacia
complex, a group of bacteria that are ubiquitous in the environment and capable of infecting people with cystic
fibrosis (CF). This species is an emerging pathogen and it has been widely isolated from CF patients in Argentina,
Spain, Portugal, Australia, Canada, USA with a low prevalence in Ireland, France, Russia, Switzerland, Czech Republic,
and Italy. This is the first report of B. contaminans affecting two Italian CF patients attending the same CF Centre.
We correlate B. contaminans colonisation with lung function decline and co-infection with other clinically relevant
CF pathogens.
Case presentation: B. contaminans was identified by Multi Locus Sequence Typing in routine sputum analysis of
two Caucasian CF women homozygous for Phe508del CFTR mutation. Sequence Type 102 was detected in both
strains. It is known that B. contaminans ST102 was isolated both from CF and non-CF patients, with an
intercontinental spread across the world. Random Amplified Polymorphic DNA analysis revealed the genetic
relatedness between the two strains. We examined their susceptibility to antimicrobial agents, comparing the latter
with that recorded for other B. contaminans isolated from different countries. We also described key virulence
factors possibly linked with a clinical outcome. Specifically, we attempted to correlate colonization with the
incidence of acute exacerbation of symptoms and lung function decline.
Conclusions: This case presentation suggests that acquisition of B. contaminans ST102 is not directly associated
with a lung function decline. We retain that the presence of other CF pathogens (i.e. MRSA and Trichosporon) along
with B. contaminans ST102 might have contributed to the worsening of clinical conditions in our CF patients. The
circumstances leading to the establishment of B. contaminans ST102 infections are still unknown. We highlight the
importance to proper detect and typing bacteria implicated in CF infection by using molecular techniques.
Keywords: Cystic fibrosis, Burkholderia contaminans, Multi locus sequence typing, Molecular typing, Lung function,
Coinfection
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Background
Bacteria of the Burkholderia cepacia complex (BCC) are
known opportunistic nosocomial pathogens causing se-
vere respiratory infections in immunocompromised
hosts and in Cystic Fibrosis (CF) patients [1]. BCC
bacteria are associated with a poor prognosis, a rapid de-
cline in lung function and reduced median survival [2].
Their heterogeneous intrinsic resistance to a wide range
of antibiotics as well as their ability to develop further
resistance during therapy make the treatment of BCC in-
fections particularly difficult in CF [3]. The development
of molecular tools has improved both the genetic
characterization of cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene and the BCC taxonomy
knowledge, properly identifying isolates at species and
lineage level [4, 5]. Actually, the group is known to en-
compass at least 20 closely related species found in many
niches of both natural and clinical environments, whose
laboratory identification can often prove difficult [6–11].
Epidemiological studies examining relationships be-
tween respiratory infection and clinical outcomes have
defined the contributions of BCC species to CF lung
disease. Over the 20 formally named species within the
complex, Burkholderia multivorans (genomovar II) and
Burkholderia cenocepacia (genomovar III) together ac-
count for approximately 85–97% of all BCC infections in
CF [12]. Although it has been well demonstrated that
lung function declines more rapidly in CF patients in-
fected with B. cenocepacia [12], also B. multivorans and
Burkholderia dolosa have been associated with severe
outcomes in CF [13–16]. Over the past several years,
potential novel BCC species have been recovered with
greater frequency from CF respiratory secretions but
predicting prognosis after their infection in CF is chal-
lenging. Among the BCC species, a growing clinical
interest concerns Burkholderia contaminans. Isolates of
both clinical and environmental origin previously identi-
fied as taxon K and included in Multilocus Sequence
Typimg (MLST) groups I and II, were identified as B.
contaminans [9], referring to the metagenome that was
recovered from the Sargasso Sea (the so-called Burkhol-
deria SAR-1 metagenome) [17]. In addition to forest soil
and river water [9], B. contaminans has been recovered
from contaminated pharmaceutical products [9] and
healthcare facilities where it has caused outbreaks [18, 19].
Over the past decade, B. contaminans is increasingly
associated with CF [20] and with hospitalized non-CF
patients [21, 22]. B. contaminans is frequently isolated
from CF respiratory samples in Ibero-America countries
[23, 24] indicating a large and characteristic geographic
distribution of considerable concern. As reported in
Multilocus Sequence Typing (MLST) database website,
B. contaminans was also detected in Italy [25] and
named as LMG 23253 (id: 126) and R-19218 (id: 2695)
[9]. To date, there are no epidemiological studies that re-
vealed the presence of other B. contaminans strains in
Italy. We describe for the first time a single Centre ex-
perience of two CF patients in which the B. contaminans
was recovered from the sputum sample and typed by
means of MLST and Random Amplified Polymorphic
DNA. To elucidate the potential clinical impact of B.
contaminans, we aimed to describe its key virulence
factors possibly linked with a clinical outcome. Specific-
ally, we attempted to correlate colonization with the
incidence of acute pulmonary exacerbation and lung
function decline.
Case presentation
In May 2008 and in June 2008 two female CF patients
were identified as B. contaminans positive at the
Regional CF Centre of Policlinico Umberto I Hospital,
Sapienza University of Rome, Italy, following MLST ana-
lysis as described by Baldwin et al. [5]. We collected
demographic and clinical characteristics, chronic infec-
tions and CF comorbidity (pancreas insufficiency and
CF-related diabetes) of both patients since they referred
to our center. We also collected information on number
of pulmonary exacerbations and exacerbation treatment
in the preceding B. contaminans detection period and
throughout the follow-up. Exacerbation events were
ascertained through a review of electronic records and
hospital charts.
Patient 1 was a Caucasian 32-year-old CF woman di-
agnosed with CF shortly after birth, due to meconium
ileus, CFTR genotype Phe508del/Phe508del. The patient
demonstrated good compliance with her treatment
regimen, complicated by insulin dependent diabetes mel-
litus CF related. From the age of 2 years she was infected
with Haemophilus influenzae 104 colony forming units
(CFU)/ml, Sthaphylococcus aureus 104 CFU/ml, Steno-
tromonas malthophilia 104 CFU/ml, and Aspergillus
flavus 104 CFU/ml. In 1992 aged 16 years, she acquired
Methicillin-resistant Staphylococcus aureus (MRSA) 104
CFU/ml and became chronically infected. Her spirom-
etry showed Forced Expiratory Volume in 1 s (FEV1) 2,
47 L (72% of predicted) and Forced Vital Capacity (FVC)
3.01 L (78% of predicted). In August 2001, MRSA and a
novel pathogen as Trichosporon 104 CFU/ml have been
recovered in her respiratory secretions. At this time, her
FEV1 dropped from 2,18 L (64% of predicted) to 1,48 L
(48% of predicted) and her body mass index (BMI) was
19,2 kg/m2. In May 2008, patient attended the CF Centre
for the annual review. Microbiological analyses of spu-
tum samples identified for the first time the presence of
B. contaminans 105 CFU/ml and showed also MRSA 106
CFU/ml, Achromobacter xylosoxidans 104 CFU/ml,
Trichosporon spp. 105 CFU/ml. Patient’s FEV1 was 43%,
her full blood count at the time showed a mildly
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elevated white cell count of 10.98 109/L, with neutrophil
count of 4.69 109/L and C-reactive protein (CRP) of
10.9 mg/dL. In August 2008, the patient was admitted
for pulmonary exacerbation and was treated with a
course on intravenous ceftazidime 50mg per kg per dose
every 8 h and oral sulfamethoxazole-trimethoprim
combined with physiotherapy. At the discharge her lung
function did not improve with FEV1 1,21 L (40% of pre-
dicted) and FVC 1,86 L (52% of predicted). After 3
months she was admitted to hospital with poor nutri-
tional status (BMI 18 kg/m2) and her FEV1 was 0,99 L
(33% predicted), her lowest recorded. High resolution
computed tomography (HRCT) showed severe bilateral
bronchiectasis, mainly in the upper lobes with associated
bronchial wall thickening and mucus retention in the
bronchial lumen. Bilateral ground-glass opacity with
areas of consolidation were also described (Fig. 1). It was
decided to adopt a 2 weeks quadruple treatment strategy
comprising IV ceftazidime 50mg per kg per dose every
8 h, IV meropenem 40mg per kg per dose, IV sulfa-
methoxazole-trimethoprim and chloramphenicol (500
mg every 6 h). Between January and July 2010, the pa-
tient required several hospital admissions for pulmonary
exacerbations all of which were treated with a
combination of IV meropenem 40mg per kg per dose,
IV tobramycin 300 mg once a day or IV Amikacin 500
mg bd, IV Linezolid 600 mg bd and IV Temocillin 2 g
every 8 h. Oxygen supplementation was also started. In
August 2010, the patient was admitted to hospital with
acute dyspnea requiring increased oxygen supplementa-
tion and atrial fibrillation. A newsputum culture confirmed
the presence of MRSA 104 CFU/ml, B. contaminans 106
CFU/ml and Trichosporon spp 106 CFU/ml. She started
antimicrobial treatment with IV meropenem, IV tobra-
mycin, IV ceftazidime, IV voriconazole 200mg bd, IV
methylprenisolone 20mg bd and IV verapamil. Her condi-
tion continued to worsen over the following 3 days with an
elevated CRP 50 g/dL. She died 48 h later due to lung
failure.
Patient 2 was a 34–year-old woman of Caucasian
origin diagnosed with CF at the 1 year of age, due to re-
spiratory symptoms. Her genotype is homozygous for
the F 508del mutation. Between diagnosis and June
2008, the patient attended the Regional Cystic Fibrosis
Centre in Rome, Italy. Her cough swabs and sputum
cultures had yielded Streptococcus viridans 104 CFU/ml
and S. aureus 106 CFU/ml. In 1984 she had also ac-
quired, and had been treated for Pseudomonas aerugi-
nosa 105 CFU/ml, which recurred in 1989,1995 and
1998. During the observation period, FEV1 and FVC
were regularly recorded and remained stable over time
(FEV1 3,12 L, 106% of predicted, FVC 3.4 L, 101% of
predicted). Attempts to eradicate P. aeruginosa failed
and she was deemed to be chronically infected in 1998.
As the strain was sensitive to tobramycin following anti-
biotics susceptibility test, she was commenced on long-
term anti-pseudomonal therapy comprising alternate
months on-off of nebulised tobramycin twice daily. Since
1998 she was also chronically infected by MRSA 106
CFU/ml. Although she had good compliance with her
medications and adherence to physiotherapy, her lung
function started to decline. In 2004 patient experienced
admission for treatment of pulmonary exacerbation and
her lung function on discharge were FEV1 1,91 L (72% of
predicted), FVC 2.43 L (79% of predicted), her lowest re-
corded. In June 2008, the patient presented for annual
review and her FEV1was 1,7 L (65% of predicted), similar
to previous annual review. MRSA was identified from
her routine sputum sample. In addition, however, B.
contaminans 105 CFU/ml was also detected, representing
Fig. 1 High Resolution Computed Tomography (HRCT) of the Patient 1′ Lungs. A) Axial and B) Coronal HRCT images showing severe bilateral
bronchiectasis, mainly in the upper lobes (black arrow), with associated bronchial wall thickening and mucus retention in bronchial lumen.
Bilateral ground-glass opacity with areas of consolidation (white arrow)
Savi et al. BMC Pulmonary Medicine          (2019) 19:164 Page 3 of 8
the second incidence in our Centre. Her sputum was
positive to B. contaminans 104 CFU/ml again in December
2008 and to date it has never been detected. Between B.
contaminans isolation and February 2017, the patient had
experience two pulmonary exacerbation treated with oral
antibiotics and both her nutritional status and pulmonary
function remained stable. She commenced Lumacaftor/
Ivacaftor therapy in February 2017. During the first year
of treatment, the patient did not have exacerbations. Her
last spirometry values increased with FEV1 2.12 L (87% of
predicted) and FVC 2.69 L (92% of predicted).
In both cases, B. contaminans was isolated from
sputum samples collected by the patients through spon-
taneous expectoration during routine visits at our CF
Centre. Samples were routinely processed according to
standard CF microbiological procedures [26]. Samples
were liquefied by the addition of Sputasol (Oxoid Ltd.
Hampshire) at a 1:1 dilution (v/v) and incubation at
37 °C for 1 h to reduce the viscosity of the sputum. Ten-
fold dilutions of treated samples (20 μl) were plated and
cultured on common appropriate media for CF patho-
gens including Burkholderia cepacia selective agar
medium (BCSA) (Bio-Mérieux Marcy-l’Etoile, France).
Plates were incubated at 35 °C for 24–48 h and then
maintained at room temperature up to 5 days. The pre-
sumptive B. cepacia complex colonies were identified as
BCC by API 20NE System (Bio-Mérieux Marcy-l’Etoile,
France) and stored at − 80 °C. The identification of the
bacterial isolate recovered from BCSA plates to the spe-
cies status of B. contaminans was subsequently assessed
following the BCC MLST scheme developed by Baldwin
and colleagues [5]. Genomic DNA was extracted from a
liquid pure culture using the cetyltrimethylammonium
bromide (CTAB) method [27]. PCR reactions and
conditions were performed as described by Baldwin and
colleagues [5] for seven independent housekeeping loci
(atpD, gltB, gyrB, recA, lepA, phaC, trpB) were amplified
by PCR as described by Baldwin and colleagues [5]. The
amplification products were purified using Sephadex G-
100 resin according to Cesarini and collegues [28]. The
nucleotide sequences of the seven amplified genetic loci
were determined using nested primers as described pre-
viously [5]. Sequencing reactions were prepared by using
Applied Biosystem Big Dye® Terminator sequencing kit
version 3.1, according to the manufacturer’s instructions
and analyzed with an ABI PRISM 310 Genetic Analyzer
Perkin-Elmer, at the ENEA Genome Research Facility
DNA Sequencing Laboratory (Genelab, ENEA C.R.
Casaccia, Italy). The forward and reverse sequences of
each locus were aligned, trimmed to the desired allele
length using SeqMan II (DNAStar software) [28], and
compared with existing alleles in the BCC MLST data-
base at http://pubmlst.org/bcc/ [29], in order to assign
the isolate allelic profile obtained with a sequence type
(ST), indicative of each genetically distinct strain [5].
The taxonomic status of isolates was determined by ST
searching against the MLST database [28]. The bacterial
isolate of the Patient 1, named CF 349, resulted to have
the Sequence Typing (ST) 102, showing the following al-
lelic profile: atpD: 64; gltB: 80; gyrB: 76; recA: 89; lepA:
105; phaC: 97; trpB: 70. The bacterial isolate of the
Patient 2, named CF 352, resulted to have the Sequence
Typing (ST) 102 as that found for CF 349 strain, show-
ing the following allelic profile: atpD: 64; gltB: 80; gyrB:
76; recA: 89; lepA: 105; phaC: 97; trpB: 70. The two bac-
terial isolates, CF 349 and CF 352, were genetically typed
by random amplified polymorphic DNA (RAPD) analysis
as described by Mahenthiralingam et al. [30]. RAPD
fingerprints were analyzed using the Quantity One
software package (Bio-Rad Laboratories, Milan, Italy) as
previously described [28]. Reproducibility was verified by
RAPD fingerprinting each isolate at least four times in
independent experiments. CF349 and CF352 isolates
were genetically related since they exhibited the same
genetic fingerprints differing by no more than two bands
(Fig. 2). Antibiotic susceptibility test of CF349 and
CF352 isolates is presented in Table 1. It was studied by
employing the Kirby-Bauer disc-diffusion method on
Mueller Hinton II Agar (Bio-Merieux Marcy l’Etoile,
France) as recommended by the Clinical and Laboratory
Standards Institute (CLSI) [31]. The results were deter-
mined by measuring the diameter of complete inhibition
of bacterial growth. Zone diameters of susceptibility test-
ing results were categorized as sensitive (S), intermediate
(I), or resistant (R) based on the CLSI breakpoint criteria
for B. cepacia for ceftazidime (CAZ), meropenem (MEM),
imipenem (IMP), trimethoprim/sulfamethoxazole (SXT),
and breakpoint criteria for P. aeruginosa for piperacillin/
tazobactam (TZP), amikacin (AK), aztreonam (ATM),
Ciprofloxacin (CIP), gentamicin (GEN) and tobramycin
(TOB).
Discussion
In this case report we described for the first time the
genetic relationships between 2 B. contaminans isolates
from two Italian CF patients attending the same CF
Centre in the same period of time. We examined the
clinical impact of this microorganism in two CF patients
and the co-infection with other CF pathogens colonizing
the patients’ respiratory tract. Strict infection control
measures followed at the Regional CF Centre of Rome,
Italy, including patient segregation, have reduced the
epidemic spread but not eliminated new BCC infections,
and CF patients may occasionally become infected by
strains showing novel fingerprint types [32]. The present
study reports the first case of B. contaminans acquisition
in our CF Centre. MLST analysis performed on BCC
strains collected from our patients did not reveal any
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other colonisation of B. contaminans during the out-
break period, in the previous years and up to date. This
finding highlighted the continuing role of BCC species
as opportunistic pathogens [33]. An accurate and rapid
species identification within BCC is fundamental to
manage BCC infections in CF patients in relation to
appropriate therapy, infection control and lung trans-
plantation. The development of molecular techniques,
that has been improving knowledge in BCC taxonomy,
enables to properly identify isolates that were previously
difficult to be characterized, helping to individuate the
strains responsible for novel acquisition [5]. The
Burkholderia cepacia complex Multi Locus Sequence
Typing website (https://pubmlst.org/bcc/) reveals the
presence of 94 B. contaminans records and/or id, having
35 different STs. ST102 includes 20 strains isolated from
environmental sources such as Sargasso sea [17], from
sheep mastitis (milk) [34], and from human sources,
including sputum and blood samples of CF and non-CF
patients in North and South America, and Europe [25].
Some strains (AU7143 LMG23252) belonging to ST102
have been involved in widespread outbreaks in the
United States and Brazil [25, 35]. Several cases of
epidemic transmission of taxon K strains among CF pa-
tients have been reported in Italy [36], and in Portugal
[37], and it is likely that environment may act as reser-
voir for novel BCC infections [38]. A positive selection
of hypermutators, linked to antimicrobial resistance
development, might be playing a key role in increasing
B. contaminans adaptability to the CF-airway environ-
ment, facilitating the persistence of chronic lung infec-
tions [39]. As results of the segregation policies followed
at the Regional Cystic Fibrosis Centre of Rome, CF pa-
tients harbour now unique BCC strains and the present
study reports the first case of B. contaminans acquisition
of closely-related strains by two patients. In the last few
years, the potential clinical impact of infection with B.
contaminans has been investigated [40]. There is evi-
dence in CF that B. contaminans infections are often of
transient nature [41] and thus can be perceived as re-
spiratory tract colonization rather than true infection
[40]. Only some patients develop chronic infection with
long-term culture positivity [24]. However, some of the
cases can get worse and result in fatalities.
The clinical experience about B. contaminans ST102
identified in our Centre was similar in both CF patients
described in this report. Specifically, lung function de-
cline and clinical deterioration were associated with the
Fig. 2 Random amplified polymorphic DNA (RAPD) fingerprints of B.
contaminans isolates generated using primer 270. Lane M, 123-bp
molecular size marker ladder. On the left, B. contaminans, CF 349
strain, recovered from Patient 1 in May 2008. On the right, B.
contaminans, CF 352 strain, recovered from Patient 2 in June 2008
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isolation of other CF pathogens along with B. contami-
nans. In effect, Patient 1 presented a deep decline of
FEV1 and nutritional status in August 2001, when
MRSA and a novel pathogen as Trichosporon spp. have
been recovered in her respiratory secretions. At the time
of first isolation of B. contaminans, lung function values
did not change in comparison to those found 1 year
before BCC colonization (FEV1 43% predicted vs 42%
predicted and FVC 54% predicted vs 56%). While the
contribution of MRSA to CF lung disease has been well
defined, the potential pathogenicity of Trichosporon spp.
was recently defined [42]. In agreement with Patient 1,
Patient 2 showed a FEV1 decline in association with
MRSA respiratory infection. Transient colonization of
the respiratory tract by B. contaminans was not associ-
ated with changes in clinical outcome measures. Both
CF patients showed a link between infection and disease
when other pathogens were recovered from culture
rather than B. contaminans isolation. At the time of B.
contaminans detection, both Patient 1 and Patient 2
were attending the same adult CF clinic. After the
identification of B. contaminans, we implemented the
strategy focused on reducing cross-infection risk (either
via direct exposures or surface contamination), and
involved clinic sterilization, reinforcement of strict isola-
tion practices and education of both members of the CF
team and patients. Containment appeared to have been
effective as B. contaminans has not been isolated in our
CF Centre since.
In conclusion, our results suggest that acquisition of B.
contaminans strain was not associated with a decline in
lung function and highlight the feature that circum-
stances leading to the establishment of B. contaminans
infections are still unknown. We retain that several
factors such as patients’ clinical characteristics and other
pathogens associated with CF pulmonary exacerbations,
along with B. contaminans acquisition, might have
contributed to the worsening of general conditions in
our CF patients. This study demonstrates that B.
contaminans infection can occur, probably due to the
wide diffusion of this species in the environment. Our
data also support an environmental/hospital origin of B.
contaminans infections. The detection and accurate
identification of the novel BCC species in CF specimens
are fundamental for the analysis of the clinical response
of CF individuals to BCC infection and are expected to
have a significant impact on future clinical management
in relation to appropriate therapy, infection control and
lung transplantation.
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